LEE'S PHARM.

Welcome to LEE'S PHARM.
I'm sorry that our content requires Adobe Flash Player.

	2015.07.03	Presentation at The First Chinese Symposium of Thrombosis and Haemostasis in Association with the ISTH Congress

	2015.03.30	First patient enrolled in Phase Ib-IIa clinical studyof Adapalene and Clindamycin combination hydrochloride Gel for Acne Vulgaris (Moderate to severe acne)

	2015.03.09	Lee’s Pharm Joins Hang Seng Broad Consumption Index, Hang Seng Mainland Consumer Goods Index, Hang Seng Global Composite Index and Hang Seng Composite Index

	2015.02.26	Lee’s Zhaoke Pharmaceutical Ranks Second in 2014 for Number of Declared New Drug Application

	2014.11.27	EyeSense Attracts Lee’s Pharmaceutical Holdings as Strategic Investor

	2014.11.19	Ikaria and Lee’s Pharmaceutical Announce Strategic Partnership for the Registration and Commercialization of Ikaria’s INOMAX ® Total Care Package in the PRC, HK, Macau and Taiwan

	2014.11.12	Lee’s Pharmaceutical successfully obtained the Imported Drug License for MICTONORM® in China

	2014.11.12	Patients Enrollment Completed in Phase II Clinical Study of Anfibatide in China

	2014.11.10	Lee’s Pharm Becomes a Constituent Stock of MSCI China Index under MSCI Global Small Cap Indexes

	2014.10.06	SORRENTO AND LEE’S PHARMACEUTICAL ENTER INTO EXCLUSIVE CHINA LICENSING AGREEMENT TO DEVELOP AND COMMERCIALIZE ANTI-PD-L1 ANTIBODY

Carnitene®

Ferplex®

ALOXI®

Zanidip®

Dafnegin®

Veloderm®

Gaslon N®

Hyalofemme®

Livaracine®

Yallaferon®

Slounase®

Eyprotor®